BIOMAT Database Logo BIOMAT Database Logo

Outcomes of Immunotherapy Versus Chemotherapy as First-Line Treatment in Advanced NSCLC: A Meta-Analysis of Randomized Clinical Trials. 2023

Ben Ponvilawan, and Parth Sharma, and Himil Mahadevia, and Janakiraman Subramanian, and Dhruv Bansal
Department of Internal Medicine, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016032 Randomized Controlled Trials as Topic Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Clinical Trials, Randomized,Controlled Clinical Trials, Randomized,Trials, Randomized Clinical

Related Publications

Ben Ponvilawan, and Parth Sharma, and Himil Mahadevia, and Janakiraman Subramanian, and Dhruv Bansal
Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis.
March 2022, Cancer treatment reviews,
Ben Ponvilawan, and Parth Sharma, and Himil Mahadevia, and Janakiraman Subramanian, and Dhruv Bansal
First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR-mutated NSCLC: a meta-analysis of randomized phase III trials.
June 2024, Expert review of anticancer therapy,
Ben Ponvilawan, and Parth Sharma, and Himil Mahadevia, and Janakiraman Subramanian, and Dhruv Bansal
Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced NSCLC.
October 2020, Immunotherapy,
Ben Ponvilawan, and Parth Sharma, and Himil Mahadevia, and Janakiraman Subramanian, and Dhruv Bansal
First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
January 2021, Frontiers in oncology,
Ben Ponvilawan, and Parth Sharma, and Himil Mahadevia, and Janakiraman Subramanian, and Dhruv Bansal
S-1-based versus 5-FU-based chemotherapy as first-line treatment in advanced gastric cancer: a meta-analysis of randomized controlled trials.
August 2014, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Ben Ponvilawan, and Parth Sharma, and Himil Mahadevia, and Janakiraman Subramanian, and Dhruv Bansal
The role of immunotherapy plus chemotherapy versus chemotherapy alone as first-line treatment for advanced non-small cell lung cancer: an updated systematic review and meta-analysis of randomized controlled trials.
October 2022, Expert review of anticancer therapy,
Ben Ponvilawan, and Parth Sharma, and Himil Mahadevia, and Janakiraman Subramanian, and Dhruv Bansal
Combination of EGFR-TKIs and chemotherapy as first-line therapy for advanced NSCLC: a meta-analysis.
January 2013, PloS one,
Ben Ponvilawan, and Parth Sharma, and Himil Mahadevia, and Janakiraman Subramanian, and Dhruv Bansal
Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC.
January 2023, Frontiers in oncology,
Ben Ponvilawan, and Parth Sharma, and Himil Mahadevia, and Janakiraman Subramanian, and Dhruv Bansal
Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis.
October 2011, Annals of oncology : official journal of the European Society for Medical Oncology,
Ben Ponvilawan, and Parth Sharma, and Himil Mahadevia, and Janakiraman Subramanian, and Dhruv Bansal
S-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis.
January 2013, PloS one,
Copied contents to your clipboard!